S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
New AI Stock Payouts (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
New AI Stock Payouts (Ad)
Things to know about California's new proposed rules for insurance companies
Analysts Went All In On These Computer Stocks, Save Your Spot
New AI Stock Payouts (Ad)
How major US stock indexes fared Friday, 9/22/2023
MarketBeat Week in Review – 9/18 - 9/22
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
New AI Stock Payouts (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
New AI Stock Payouts (Ad)
Things to know about California's new proposed rules for insurance companies
Analysts Went All In On These Computer Stocks, Save Your Spot
New AI Stock Payouts (Ad)
How major US stock indexes fared Friday, 9/22/2023
MarketBeat Week in Review – 9/18 - 9/22
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
New AI Stock Payouts (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
New AI Stock Payouts (Ad)
Things to know about California's new proposed rules for insurance companies
Analysts Went All In On These Computer Stocks, Save Your Spot
New AI Stock Payouts (Ad)
How major US stock indexes fared Friday, 9/22/2023
MarketBeat Week in Review – 9/18 - 9/22
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
New AI Stock Payouts (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
New AI Stock Payouts (Ad)
Things to know about California's new proposed rules for insurance companies
Analysts Went All In On These Computer Stocks, Save Your Spot
New AI Stock Payouts (Ad)
How major US stock indexes fared Friday, 9/22/2023
MarketBeat Week in Review – 9/18 - 9/22
OTCMKTS:AZNCF

AstraZeneca (AZNCF) Stock Forecast, Price & News

$137.93
+3.98 (+2.97%)
(As of 09/22/2023 ET)
Compare
Today's Range
$137.93
$137.93
50-Day Range
$130.08
$147.00
52-Week Range
$104.50
$153.10
Volume
731 shs
Average Volume
3,089 shs
Market Capitalization
N/A
P/E Ratio
169.03
Dividend Yield
2.03%
Price Target
$13,500.00

AstraZeneca MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
9,687.6% Upside
$13,500.00 Price Target
Short Interest
Bearish
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.09mentions of AstraZeneca in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars


AZNCF stock logo

About AstraZeneca (OTCMKTS:AZNCF) Stock

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZNCF Price History

AZNCF Stock News Headlines

20 Best Healthcare Dividend Stocks to Invest in (AZNCF)
Healthcare, like many other sectors, produces dividends. Learn more about how to invest in healthcare trends and earn dividends along the way with MarketBeat.
Breast cancer drug trial boosts AstraZeneca
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
AstraZeneca, Daiichi Breast Cancer Drug Shows Benefits
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Short Interest in AstraZeneca PLC (OTCMKTS:AZNCF) Expands By 10.7%
See More Headlines
Receive AZNCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZNCF Company Calendar

Ex-Dividend for 9/11 Dividend
8/09/2023
Dividend Payable
9/11/2023
Today
9/23/2023

Industry, Sector and Symbol

Industry
Drug Manufacturers—General
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:AZNCF
Fax
N/A
Employees
83,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13,500.00
High Stock Price Forecast
$13,500.00
Low Stock Price Forecast
$13,500.00
Forecasted Upside/Downside
+9,687.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Pascal Soriot D.V.M. (Age 64)
    M.B.A., CEO & Exec. Director
    Comp: $5.92M
  • Dr. Aradhana Sarin M.D. (Age 48)
    Exec. Director
    Comp: $3.39M
  • Ms. Pam P. Cheng (Age 52)
    EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
  • Mr. Andrew P. Barnett
    Head of Investor Relations
  • Mr. Jeffrey Pott
    CHRO, Chief Compliance Officer, Gen. Counsel & Member of External Sustainability Advisory Board
  • Gonzalo Vina
    Head of Global Media Relations
  • Dr. Menelas Pangalos Ph.D. (Age 56)
    EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
  • Dr. Ruud Dobber Ph.D.
    Exec. Vice-Pres of BioPharmaceuticals Bus. Unit
  • Dr. Susan Mary Galbraith M.D. (Age 57)
    Ph.D., Exec. VP of Oncology R&D
  • Mr. Leon Wang
    Exec. VP of International & China Pres













AZNCF Stock - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AZNCF shares.
View AZNCF analyst ratings
or view top-rated stocks.

What is AstraZeneca's stock price forecast for 2023?

1 analysts have issued 12 month target prices for AstraZeneca's stock. Their AZNCF share price forecasts range from $13,500.00 to $13,500.00. On average, they expect the company's share price to reach $13,500.00 in the next twelve months. This suggests a possible upside of 9,687.6% from the stock's current price.
View analysts price targets for AZNCF
or view top-rated stocks among Wall Street analysts.

How have AZNCF shares performed in 2023?

AstraZeneca's stock was trading at $139.28 at the beginning of the year. Since then, AZNCF shares have decreased by 1.0% and is now trading at $137.93.
View the best growth stocks for 2023 here
.

Are investors shorting AstraZeneca?

AstraZeneca saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 99,300 shares, an increase of 10.7% from the August 15th total of 89,700 shares. Based on an average daily volume of 4,400 shares, the days-to-cover ratio is currently 22.6 days.
View AstraZeneca's Short Interest
.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a dividend on Saturday, July 29th. Investors of record on Friday, August 11th will be paid a dividend of $0.93 per share on Monday, September 11th. The ex-dividend date of this dividend is Wednesday, August 9th.
Read our dividend analysis for AZNCF
.

Is AstraZeneca a good dividend stock?

AstraZeneca (OTCMKTS:AZNCF) pays an annual dividend of $2.80 per share and currently has a dividend yield of 3.89%. The dividend payout ratio is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for AZNCF.

What is AstraZeneca's stock symbol?

AstraZeneca trades on the OTCMKTS under the ticker symbol "AZNCF."

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by a number of retail and institutional investors. Top institutional investors include Boston Common Asset Management LLC (0.00%).

How do I buy shares of AstraZeneca?

Shares of AZNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AstraZeneca's stock price today?

One share of AZNCF stock can currently be purchased for approximately $137.93.

How many employees does AstraZeneca have?

The company employs 83,500 workers across the globe.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom. The official website for the company is www.astrazeneca.com. The company can be reached via phone at 442037495000.

This page (OTCMKTS:AZNCF) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -